The Real Cost of Carrying Stale Underwriting Evidence Into Renewal

How a Small Recency Gap at Issue Turns Into a Multi-Year Margin Problem

A stale piece of underwriting evidence rarely causes a single bad quarter. It causes something worse, a slow, compounding drag on margin that keeps surfacing renewal after renewal.

This matters most in life and health reinsurance precisely because the evidence gathered at issue is meant to hold for decades. A recency gap that looks trivial on one policy becomes a meaningfully different reserve and profitability picture once the business has fully seasoned.

The risk-diagnosis side of this problem, why evidence ages in the first place, is covered in why underwriting evidence ages too quickly for reinsurers to trust. This post turns that diagnosis into a dollar figure.

How Exactly Does Stale Evidence Hit Margin?

It hits margin in one of two directions, and both are costly.

If a reinsurer prices off evidence that understates true risk, because it was collected before a material health change, the treaty is underpriced from day one. Every claim that follows chips away at margin that was never really there.

The reverse is just as damaging. If underwriting overcorrects and treats aging evidence as automatically worse than it is, pricing runs too conservative, cedants shop the business elsewhere, and the reinsurer loses volume it could have profitably retained.

Either direction traces back to the same root cause, evidence that no longer matches the applicant it was collected from.

Why Does the Cost Build Slowly Instead of Appearing Immediately?

The cost builds slowly because claims on long-duration life business take years to emerge.

A policy underwritten on stale evidence does not reveal its mispricing in the first reporting period. It reveals it gradually, as actual-to-expected ratios drift and as more of the in-force block reaches the point in its life cycle where the evidence gap starts mattering.

By the time the cumulative effect shows up in headline profitability, several renewal cycles of business have already been written on the same underlying practice. That lag is exactly why early detection matters more than after-the-fact correction, and why waiting for the numbers to show it is the most expensive way to find out.

Does the GLP-1 Case Illustrate This Timing Problem Well?

Yes, because the risk can reappear mid-policy, not just at issue.

RGA's research notes that if GLP-1 treatment stops, "the weight gain that occurs... may be dramatic," bringing "concomitant increases in mortality and morbidity risk throughout the duration of the policy." That is a risk event with no natural repricing trigger attached to it.

A treaty priced on evidence collected while an applicant was on treatment can end up carrying meaningfully different risk years later if treatment stops. Nothing in a standard renewal process is designed to catch that shift.

Which Portfolios Carry the Most Exposure to This Cost?

Long-duration treaties with limited repricing flexibility carry the greatest exposure.

A yearly renewable term treaty gets repriced annually, which caps how far a stale-evidence gap can travel before it gets corrected. A twenty or thirty-year life treaty, or a coinsurance arrangement with no annual repricing point, carries the original gap forward for the full duration.

That distinction should shape how a reinsurer prioritizes which parts of its book to review first. Treaties with the longest duration and the least repricing flexibility deserve the earliest evidence-recency audit, not the last one.

How Does This Interact With Capital Requirements?

If reserving assumptions lag real evidence practices, required capital can be understated exactly when true risk has increased.

Profitability and capital adequacy move together here. A reserving methodology built on the same evidence-recency assumptions used in pricing inherits the same blind spot, understating reserves at the moment the underlying risk is actually higher than assumed.

A reinsurer that tracks profitability without also stress-testing capital against evidence-recency scenarios is only looking at half the exposure. The other half sits quietly in the reserve calculation until an actuarial review forces it into view.

How Should Executives Quantify This Cost Before It Shows Up in Reported Numbers?

Executives should model the exposure using staleness scenarios applied against the current in-force block, rather than waiting for it to surface in claims data.

The practical version of this exercise is a scenario table. Take the long-duration portion of the book, apply a low, medium, and high evidence-staleness assumption, and translate each into a present-value margin and capital impact.

That turns an abstract underwriting-practice concern into a number a CFO or board can act on immediately. A reinsurer walking into a renewal negotiation with that number already modeled has a materially stronger position than one relying on a general sense that evidence practices vary by cedant.

How Should This Cost Be Communicated to Cedants at Renewal?

It should be communicated as a specific, cohort-level figure, not a general appeal to industry uncertainty.

Cedants respond very differently to "rates need to increase because evidence practices vary" than to a breakdown showing which cohorts carry evidence older than a defined threshold, and what that translates to in basis points of margin impact. The second version is a negotiation position grounded in shared, verifiable data.

Reinsurers using tools like an Underwriting Document Verification AI Agent can produce exactly this kind of cohort-level evidence-age breakdown as a standard part of renewal preparation. That data also strengthens retrocession conversations, where a reinsurer ceding this same risk further upstream needs to describe the exposure just as concretely to its own retrocessionaire.

The decision-rights question, who inside a reinsurer actually owns setting and enforcing evidence-recency standards, is a separate problem from the cost itself, and one that is covered directly in the decision rights needed to control underwriting evidence that ages too quickly.

What Happens if This Cost Is Left Unquantified?

It keeps accruing, silently, on every treaty written under the same evidence-recency practice.

Margin erosion from stale evidence is not a one-time event to absorb and move on from. It is a compounding cost that continues until the underlying evidence-recency practice is actually changed, not just noticed.

That is exactly why the size of the gap, not just its existence, needs to be quantified and tracked continuously. A reinsurer that treats this as a one-off finding rather than an ongoing metric will keep rediscovering the same cost at every renewal cycle, just with a bigger number attached each time.

How Does This Compare to Other Margin Risks Reinsurers Already Track?

This risk is structurally similar to mortality improvement assumption drift, which reinsurers already treat as a standing, measured exposure rather than an occasional concern.

Both risks share the same shape, an assumption made at pricing that quietly stops matching reality, with the gap only becoming visible after several years of seasoning. Reinsurers have already built governance, monitoring, and reporting discipline around mortality improvement drift, largely because actuarial bodies and rating agencies have pushed the industry toward treating it as a standing metric.

Evidence-recency risk has not received the same treatment yet, even though the underlying mechanism, and the underlying cost, are comparable. A reinsurer that already has a mature process for tracking mortality improvement drift has most of the organizational muscle needed to build a parallel process for evidence-recency risk, it simply has not been asked to point that same discipline at this specific input yet.

What Data Would Make This Cost Easier to Defend to Rating Agencies?

A documented, cohort-level evidence-age distribution across the in-force book, paired with the scenario-based margin and capital impact already described.

Rating agencies increasingly expect reinsurers to demonstrate active management of assumption risk, not just disclose that assumptions exist. A reinsurer that can show a rating agency a specific evidence-recency monitoring process, with real data behind it, is demonstrating exactly the kind of proactive risk management rating agencies look for when assessing management quality.

The alternative, having no answer when this question comes up in a rating review, forces a defensive conversation instead of a demonstrative one. Building this data set now, before it is requested, is a materially better position than assembling it under time pressure during an active rating review.

How Should This Cost Be Weighed Against the Cost of Fixing It?

The cost of building evidence-recency monitoring is small and one-time, while the cost of not building it is ongoing and compounding, which makes this an easy comparison once both sides are actually quantified.

Executives evaluating whether to invest in evidence-recency tracking often compare the visible, immediate cost of new tooling or process against an invisible, abstract future risk. That comparison is skewed from the start, because one side of it has a number attached and the other does not.

Running the scenario analysis described earlier in this post before making that investment decision puts both sides on equal footing. Once the ongoing margin cost has a real number attached to it, the relatively modest, one-time cost of building monitoring capability becomes a straightforward return-on-investment case rather than a discretionary spending request competing against better-quantified priorities.

Framing the request this way, as a return-on-investment case rather than a defensive risk-management ask, also tends to move faster through internal budget approval, since it gives finance leadership a comparison they can evaluate on familiar terms instead of a qualitative risk argument they have to take largely on faith.

The margin cost of aging evidence is measurable long before it becomes visible in loss ratios, and the reinsurers that measure it early are the ones who walk into renewal negotiations with a number instead of a hunch.

Sources

• RGA: RGA GLP-1 Study: Weighing the Evidence
• RGA: Accelerated Underwriting: Maximizing its Future